Relmada Therapeutics Inc (RLMD)

$6.07 -0.18 (-2.88%)
Market Cap 445.14M
Revenue (ttm) 0.00
Net Income (ttm) -79.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,570,500
Avg Vol 1,631,928
Day's Range N/A - N/A
Shares Out 73.33M
Stochastic %K 15%
Beta 0.72
Analysts Strong Sell
Price Target $13.00

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 629 1376
Address:
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States
IN0V8
IN0V8 Mar. 20 at 4:10 PM
$RLMD Watch / Opportunity Mizuho raises target price to $19 from $10
0 · Reply
anachartanalyst
anachartanalyst Mar. 20 at 2:01 PM
$RLMD https://anachart.com/wp-content/uploads/ana_temp/1774015290_soc-img.jpg
0 · Reply
shehww
shehww Mar. 20 at 1:55 PM
$RLMD next stop 8+
0 · Reply
teaman60
teaman60 Mar. 19 at 11:03 PM
$RLMD as I have said previously,this company will never be able to get their drug to market. They will have to sell their rights to a big pharma
0 · Reply
teaman60
teaman60 Mar. 19 at 10:28 PM
$RLMD this will dump hard at opening
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 19 at 9:14 PM
$RLMD Q4 '25 Earnings Results & Recap Relmada Therapeutics Inc. reported a net loss of $57,385,163, or $1.45 per common share, for the year ended December 31, 2025, and had negative operating cash flows of $45,786,988.
0 · Reply
shehww
shehww Mar. 19 at 8:29 PM
$RLMD very positiv news 💪🔥💥💥🔥
2 · Reply
CrestFresh
CrestFresh Mar. 19 at 2:42 PM
$RLMD earnings AH?
0 · Reply
shehww
shehww Mar. 17 at 9:23 PM
$RLMD
0 · Reply
Sowa5000
Sowa5000 Mar. 13 at 2:43 PM
$PALI $RLMD $IBRX $SLS Some winners here I will be buying and holding! Get them while they are cheap!
1 · Reply
Latest News on RLMD
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

Mar 19, 2026, 10:12 PM EDT - 2 days ago

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Mar 19, 2026, 4:01 PM EDT - 2 days ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Mar 12, 2026, 7:00 AM EDT - 9 days ago

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Mar 9, 2026, 4:30 PM EDT - 12 days ago

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 9, 2026, 7:05 AM EDT - 12 days ago

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Mar 9, 2026, 7:00 AM EDT - 12 days ago

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Jan 12, 2026, 7:00 AM EST - 2 months ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Dec 3, 2025, 7:30 AM EST - 3 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:21 PM EST - 4 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 13, 2025, 4:01 PM EST - 4 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 7, 2025, 7:30 AM EST - 4 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:09 AM EST - 4 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Nov 4, 2025, 7:01 AM EST - 4 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Oct 7, 2025, 7:30 AM EDT - 5 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 16, 2025, 9:00 AM EDT - 6 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Relmada Issues Mid-Year CEO Letter to Shareholders

Sep 10, 2025, 7:15 AM EDT - 6 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 1:55 PM EDT - 8 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 31, 2025, 7:00 AM EDT - 8 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 15, 2025, 8:00 AM EDT - 8 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jul 9, 2025, 8:00 AM EDT - 9 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:02 PM EDT - 11 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 11 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 8, 2025, 7:30 AM EDT - 11 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 28, 2025, 1:38 PM EDT - 11 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 11 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:07 PM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

IN0V8
IN0V8 Mar. 20 at 4:10 PM
$RLMD Watch / Opportunity Mizuho raises target price to $19 from $10
0 · Reply
anachartanalyst
anachartanalyst Mar. 20 at 2:01 PM
$RLMD https://anachart.com/wp-content/uploads/ana_temp/1774015290_soc-img.jpg
0 · Reply
shehww
shehww Mar. 20 at 1:55 PM
$RLMD next stop 8+
0 · Reply
teaman60
teaman60 Mar. 19 at 11:03 PM
$RLMD as I have said previously,this company will never be able to get their drug to market. They will have to sell their rights to a big pharma
0 · Reply
teaman60
teaman60 Mar. 19 at 10:28 PM
$RLMD this will dump hard at opening
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 19 at 9:14 PM
$RLMD Q4 '25 Earnings Results & Recap Relmada Therapeutics Inc. reported a net loss of $57,385,163, or $1.45 per common share, for the year ended December 31, 2025, and had negative operating cash flows of $45,786,988.
0 · Reply
shehww
shehww Mar. 19 at 8:29 PM
$RLMD very positiv news 💪🔥💥💥🔥
2 · Reply
CrestFresh
CrestFresh Mar. 19 at 2:42 PM
$RLMD earnings AH?
0 · Reply
shehww
shehww Mar. 17 at 9:23 PM
$RLMD
0 · Reply
Sowa5000
Sowa5000 Mar. 13 at 2:43 PM
$PALI $RLMD $IBRX $SLS Some winners here I will be buying and holding! Get them while they are cheap!
1 · Reply
teaman60
teaman60 Mar. 13 at 2:17 PM
$RLMD Uh oh, zacks shorting this. Always a bad sign
0 · Reply
ZacksResearch
ZacksResearch Mar. 12 at 5:34 PM
$RLMD surges 42% in a week — what's fueling the rally? 🚀 Positive interim data from RLMD's phase II study shows a 76% 12-month complete response rate for NMIBC patients, with an 80% rate in the BCG-unresponsive subgroup. The candidate demonstrated strong durability and favorable safety, setting the stage for a phase III RESCUE program targeting two NMIBC settings. Discover the full potential of RLMD's NDV-01 here 👉 https://www.zacks.com/stock/news/2883316/rlmd-stock-surges-42-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2883316-body-37238&ADID=SYND_STOCKTWITS_TWEET_2_2883316_BODY_37238
0 · Reply
ZacksResearch
ZacksResearch Mar. 12 at 4:34 PM
$RLMD just ripped 42% in a week — and the catalyst is clinical data. 🚀 Relmada Therapeutics reported encouraging efficacy and safety results from a mid-stage bladder cancer study of NDV-01 and simultaneously outlined plans for a phase III trial. See what’s driving the momentum 👉 https://www.zacks.com/stock/news/2883316/rlmd-stock-surges-42-in-a-week-heres-what-you-should-know?cid=sm-stocktwits-2-2883316-teaser-37226&ADID=SYND_STOCKTWITS_TWEET_2_2883316_TEASER_37226
0 · Reply
shehww
shehww Mar. 12 at 4:26 PM
$RLMD
0 · Reply
shehww
shehww Mar. 12 at 3:55 PM
$RLMD
0 · Reply
teaman60
teaman60 Mar. 12 at 1:32 PM
$RLMD Acting as I said it would. $5.25 By next Friday and should bottom at $4.75
0 · Reply
teaman60
teaman60 Mar. 11 at 7:11 PM
$RLMD I know my penny stocks lol
0 · Reply
AdvancedOperati
AdvancedOperati Mar. 11 at 3:58 PM
$RLMD appliedmarketconcepts.us/systematic-trading-concepts-library.html
0 · Reply
teaman60
teaman60 Mar. 11 at 3:52 PM
$RLMD As expected, it will retrace at least 50% of Mondays gains. It's a penny stock
0 · Reply
CrestFresh
CrestFresh Mar. 11 at 1:58 PM
$RLMD cooking up some day 3 action perhaps?
0 · Reply
shehww
shehww Mar. 11 at 1:53 PM
$RLMD I expected more; these fluctuations are quite normal. RLM is partly shorted, and stop-loss orders are also triggered, causing the price to dip slightly. The news was very good, and with an additional 160 million private investors, I think it will reach at least 8 or 9 in the next few days. This is not a buy or sell recommendation; everyone has to decide for themselves what to do with their investment.
0 · Reply
Minnie23
Minnie23 Mar. 11 at 1:33 PM
$RLMD can we run today ?
0 · Reply